Lenacapavir' was developed by Gilead Sciences, a research-based biopharmaceutical company in the US, as a pre-exposure prophylaxis (PrEP) medication to prevent infection in people at risk of exposure ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops the ...

Funding cuts have disrupted HIV prevention, treatment, and care programmes, putting PLHIV at higher risk of infections and ...

Enormous progress has been made in tackling the global HIV epidemics over the past two decades. The number of people dying ...

An annual injection to prevent HIV infection is closer to becoming reality after the first stage of a drug trial showed promising results.

Dayton & Montgomery County Public Health hosted its ninth annual “Rocking our Red Pumps” event on Friday to recognize ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...